Asembia's Specialty
Pharmacy Summit
“As the specialty pharmacy market becomes increasingly competitive, having clear conversations on defining value from the patient perspective is imperative.”
“Evolution of Biden’s Healthcare Agenda in an Election Year” on Wednesday, May 4, 3 PM PT
Hear Our Perspective
Tune in to the 3-minute videos below for key highlights on navigating patient-centered opportunities and how specialty pharmacies are engaging with manufacturers and payers to help provide better care management, greater adherence, and improved retention activities.
Learn about how patient support services in specialty pharmacy can help patients through their journey. We’ll cover the evolving coverage landscape, the impacts of medication affordability, copay accumulators and copay maximizers, free drug programs, and growth in wraparound services.
Explore the ways that today’s specialty pharmacies act as intermediaries with manufacturers and payers helping patients with rare or complex diseases achieve better outcomes.
Hear more on the state of the Biden administration’s healthcare agenda in an election year and its impact on stakeholders, especially with Medicare Part D.
Meet Our
Experts
Associate Principal
Market Access & Reimbursement
Senior Vice President
Center for Healthcare Transformation
Practice Director
Market Access & Reimbursement
Principal
Market Access & Reimbursement
Managing Director
Market Access & Reimbursement
Associate Principal
Market Access & Reimbursement
Senior Advisor
Market Access & Reimbursement
Managing Director
Market Access & Reimbursement
Our experts will be available to discuss these priority topics
Maximizing Payer Engagement
Top-tier payer engagement is built upon an intimate knowledge of payer incentives and decision making and an understanding of how to add value beyond rebating.
US Drug Pricing Policy and Regulatory Interventions
Despite being an election year, Congress still has the incentive and time to pass drug pricing legislation. Additionally, the Biden administration will likely advance drug pricing priorities through regulatory means.
Patient-Centric Evidence Development
Increasingly, payers and providers are demanding non-traditional evidence to answer questions about how different types of patients fare in real-world treatment settings.
Related
Insights
Our market access practice supports biopharma companies with services that span the entire product life cycle, including market sizing, clinical development strategy, distribution channel planning, pricing, provider and payer insights, and digital health.
